What the trials showed
Not graded yet. Sources are listed below.
What the internet says
“Selank is a proven anxiety treatment.”
The gap
Not measured until the claim is graded.
A verdict describes the research, not what’s right for you.
Selank
Synthetic heptapeptide (tuftsin analog)
Also known as: TP-7, Selank acetate
Classification
Peptide
Regulatory Status
not-established
Sources
3
Review
reviewed · 2026-10-14
Overview
Selank is a synthetic heptapeptide tuftsin analog developed in Russia; proposed mechanisms include modulation of enkephalin-degrading enzymes. US clinical mechanism is not established by an FDA-approved label.
Evidence and limitations
What people claim, and what the evidence says
- NOT YET GRADED
“Selank is a proven anxiety treatment.”
Awaiting the two-reviewer evidence council.
- NOT YET GRADED
“Selank has been shown safe in people.”
Awaiting the two-reviewer evidence council.
Known
- Not FDA-approved; bulk nomination withdrawn on FDA compounding safety page.
Unknown
- No FDA-approved US label or large international double-blind RCT program equivalent to modern anxiolytic standards was located.
- Dependence/withdrawal claims in marketing are not supported by dedicated trial endpoints in the retrieved literature.
- Community-reported doses: n/a (no citable source).
Studied uses
- studied anxiolytic use for generalized anxiety / neurasthenia (primarily Russian literature); not FDA-approvednot indicatedStudied in Russian clinical literature as an anxiolytic; registered historically in Russia as an intranasal product. Not FDA-approved in the United States. Educational reference only.
Dangers and side effects
Contraindications
- No FDA-approved US product label; hypersensitivity risk to peptide components is a practical concern (high)Unapproved in US; compounded/gray-market intranasal or injectable products carry identity and contamination risk.
Warnings
- FDA withdrawn bulk-nomination materials note immunogenicity/impurity concerns and limited human safety data for US compounding evaluation (review)Russian product experience is not equivalent to FDA approval.
Common: not well characterized in FDA-reviewed labeling; nasal irritation reported in some peptide nasal products generally
- Serious
- risk profile not established by US approved labeling; immunogenicity is a stated practical concern for unapproved peptides
Study details: trial conditions, not guidance
These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.
Doses found
Doses as found in each source, with its grade. What was found, not a direction.
Studies, trials and professional sources
n/a
Reddit, Facebook, Instagram, forums and blogs
n/a
Claims and grades
- Plausible TheorySelank is indexed (PubChem CID 11765600; UNII TS9JR8EP1G; CAS 129954-34-3).
- Early EvidenceA Russian clinical study (PMID 18454096) compared selank with medazepam in GAD/neurasthenia (small sample; randomization/blinding details incompletely verified from abstract).
- EstablishedNot FDA-approved; bulk nomination withdrawn on FDA compounding safety page.
Contested
- Vendor marketing equates selank to benzodiazepines without dependence risk, overstating a small unreplicated evidence base.
Sources (3)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (opens in a new tab) · U.S. Food and Drug Administration · regulator
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (opens in a new tab) · Zhurnal Nevrologii i Psikhiatrii / PubMed · paper · 2008-01-01
- Selank | CID 11765600 (opens in a new tab) · NCBI / PubChem · other
Pathways
enkephalin-degrading enzyme inhibition (proposed)
Interactions & cautions
Drug interactions
benzodiazepines or other CNS-active anxiolytics — Additive sedation or confounded response monitoring is possible but not established in an FDA interaction table. (review)
These are observational flags for review, not individualized instructions.
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
not well characterized in FDA-reviewed labeling; nasal irritation reported in some peptide nasal products generally · risk profile not established by US approved labeling; immunogenicity is a stated practical concern for unapproved peptides
Effects measured:
studied anxiolytic use for generalized anxiety / neurasthenia (primarily Russian literature); not FDA-approved
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw